Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer

Results of this real-world retrospective analysis of 3,133 patients with early HR+ HER2- breast cancer highlights the risk of recurrence among patients treated with adjuvant endocrine therapy. The researchers concluded that these data underscore the need for improved treatment options for this patient population.